ASH 2020 | Umbralisib plus ublituximab vs. standard of care chemoimmunotherapy in CLL
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses the results of the Phase III UNITY-CLL trial (NCT02612311), which evaluated umbralisib plus ublituximab (U2) in comparison to obinutuzumab plus chlorambucil (O+Chl) in chronic lymphocytic leukemia (CLL) patients. U2 combines dual PI3Kδ- CK1ε inhibitor that shows less toxicity than other PI3K inhibitors, and a novel anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity capabilities. The results from over 400 randomized patients found that U2 treatment had a good safety profile and significantly improved progression-free survival (PFS) compared to standard of care O+Chl chemoimmunotherapy in relapsed/refractory and treatment-naïve patient subgroups. The overall response rate was also improved. The trial marks the first successful Phase III of a PI3K inhibitor versus chemoimmunotherapy in CLL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultancy: AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Yingli Pharmaceuticals
Research Grants: AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem
All payments made to Sarah Cannon Research Institute, not to the physician
